TITLE

Nutritional & Pharmacologic Management of Hyperlipoproteinemia

AUTHOR(S)
Edward Pickering, J.
PUB. DATE
September 1982
SOURCE
Angiology;Sep1982, Vol. 33 Issue 9, p577
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The results of the nutritional intervention on one of the twenty MRFIT centers is presented. The reduction in cholesterol was 5.78% after four years. Those results were compared with the changes found in serum cholesterol with a similar diet and the administration of either clofibrate or gemfibrozil. The reduction with clofibrate remained at 5%. However with gemfibrozil the reduction in cholesterol was 16%. The HDL level rose in half of these patients treated with either clofibrate or gemfibrozil. The results without concurrent dietary restriction usually show a greater reduction in VLDL and a greater rise in HDL than we found when nutritional and pharmacologic intervention were combined.
ACCESSION #
16525303

 

Related Articles

  • Primary Type V Hyperlipoproteinemia. Greenberg, Barry H.; Blackwelder, William C.; Levy, Robert I. // Annals of Internal Medicine;Nov77, Vol. 87 Issue 5, p526 

    Presents information on a study which described the clinical and biochemical characteristics of kindreds that were identified through propositi with primary type V hyperlipoproteinemia Methods; Results; Discussion.

  • Management of Type IV Hyperlipoproteinemia. Smith, L. Kent; Luepker, Russell V.; Rothchild, Sarah S.; Gillis, Albert; Kochman, Leon; Warbasse, J. Richard // Annals of Internal Medicine;Jan76, Vol. 84 Issue 1, p22 

    Presents a study which examined the clinical approaches for the management of type IV hyperlipoproteinemia. Association of lipoprotein diseases, particulary type IV hyperlipoproteinemia with atherosclerotic disease; Methods; Results and discussion.

  • Hyperlipoproteinemia: Problems in Diagnosis and Challenges Posed by the "Type III" Disorder.  // Annals of Internal Medicine;Feb75, Vol. 82 Issue 2, p273 

    Editorial. Presents an article on the examination of the incidence of type III hyperlipoproteinemia. Information on the electrophoresis of lipoproteins in relation to the disease; Description of patients with the disease.

  • Epidemiological Survey of Dyslipidemia in Civil Aviators in China from 2006 to 2011. Rongfu Zhao; Dan Xiao; Xiaoying Fan; Zesong Ge; Linsheng Wang; Tiecheng Yan; Jianzhi Wang; Qixin Wei; Yan Zhao // International Journal of Endocrinology;2014, p1 

    Aim. This study aimed to analyze blood lipid levels, temporal trend, and age distribution of dyslipidemia in civil aviators in China. Methods. The 305 Chinese aviators were selected randomly and followed up from 2006 to 2011. Their total cholesterol (TC), triglyceride (TG), high-density...

  • Cholestyramine in Type II Hyperlipoproteinemia. Levy, R.I.; Frederickson, D.S.; Stone, N.J.; Bilheimer, D.W.; Brown, W.V.; Glueck, C.J.; Gotto, A.M.; Herbert, P.N.; Kwiterovich, P.O.; Langer, T.; LaRosa, J.; Lux, S.E.; Rider, A.K.; Schulman, R.S.; Sloan, H.R. // Annals of Internal Medicine;Jul73, Vol. 79 Issue 1, p51 

    Presents a study which examined the efficacy of chlorestyramine in the treatment of type II hyperlipoproteinemia. Patients and methods; Results; Discussion.

  • Hyperlipoproteinemia.  // Diseases & Disorders: A Nursing Therapeutics Manual, 2nd edition;2002, p471 

    Provides information on hyperlipoproteinemia, a condition characterized by increased lipids in the blood that causes decreased rate of lipoprotein breakdown. Types of hyperlipoproteinemia; Causes of hyperlipoproteinemia; Diagnosis and clinical management of hyperlipoproteinemia.

  • Postprandial hypertriglyceridaemia in patients with Tangier disease. Kolovou, O.; Daskalova, D.; Anagnostopoulou, K.; Hoursalas, I.; Voudris, V.; Mikhailidis, D. P.; Cokkinos, D. V. // Journal of Clinical Pathology;Dec2003, Vol. 56 Issue 12, p937 

    Background: Tangier disease (TD) is the phenotypic expression of rare familial syndromes with mutations in the ABCA1 transporter. TD results in extremely low high density lipoprotein (HDL) cholesterol and reduced low density lipoprotein cholesterol, with normal or mildly increased fasting...

  • Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. Frikke-Schmidt, Ruth; Nordestgaard, Borge G.; Jensen, Gorm B.; Tybaerg-Hansen, Anne // Journal of Clinical Investigation;Nov2004, Vol. 114 Issue 9, p1343 

    Homozygosity for mutations in ABC transporter A1 (ABCA1) causes Tangier disease, a rare HDL-deficiency syndrome. Whether heterozygosity for genetic variation in ABCA1 also contributes to HDL cholesterol (HDL-C) levels in the general population is presently unclear. We determined whether...

  • Tangier disease. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p728 

    An encyclopedia entry for "Tangier disease" is presented. It refers to a rare autosomal recessive disorder which involves the build up of cholesterol in various organs of the body.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics